Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma
- 1 January 1996
- journal article
- review article
- Published by Elsevier in Surgical Oncology
- Vol. 5 (2) , 49-63
- https://doi.org/10.1016/s0960-7404(96)80001-6
Abstract
No abstract availableKeywords
This publication has 121 references indexed in Scilit:
- CA 494—a new tumor marker for the diagnosis of pancreatic cancerInternational Journal of Cancer, 1993
- Serum immunoreactive elastase in diagnosis of pancreatic diseasesDigestive Diseases and Sciences, 1987
- Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinomaCancer, 1986
- Sialosyllactotetraosylceramide, a novel ganglioside antigen detected in human carcinomas by a monoclonal antibodyFEBS Letters, 1985
- The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignanciesJournal of Molecular Medicine, 1985
- Rezidivdiagnostik und Verlaufsbeurteilung von Pankreaskarzinomen: Kombinierter Einsatz der Sonographie und des neuen »Tumormarkers« CA 19-9Deutsche Medizinische Wochenschrift (1946), 1984
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- A reappraisal of the value of carcinoembryonic antigen in the management of patients with various neoplasmsBritish Journal of Surgery, 1979
- A Cancer-Associated Galactosyltransferase IsoenzymeNew England Journal of Medicine, 1978
- Free and bound carcinoembryonic antigen in neoplasms and in normal adult and fetal tissueImmunochemistry, 1974